A revolutionary approach to predict human safety in immunisation programmes involving human stem cells
Dr Subhadra Dravida, Founder CEO, Transcell Biologics explains about NeuroSAFE technology which can be used to predict human safety in immunisation programmes involving human stem cells
In October 2021[1], after a three-decade wait a vaccine for leading killer disease malaria was finally approved. Since traditional safety testing methods such as the monkey-based neurovirulence testing (MNVT) are usually time consuming, such delays are factored into the process. However, since the SARS‐CoV‐2 virus upended the world, even the pharma industry needed to deliver a family of vaccines on a deadline. And despite mandated screenings, some of them are being marked for breaching safety concerns and causing cardiotoxicity, neurovirulence or even Guillain-Barré Syndrome, as was documented after administering certain vaccinations[2].